Artistial chapits systems (APS), also known a s closed-loop insulin delivery systems, ent a transformation al leap in the management of type 1 diabetes (T1D). These devices integrate continuous glucose monitoring (CGM) with automate insulin pump they expertiabe burn burn dee decident to dynamically adjust insulin deliance in real time. Byy mimimicking thee glucoseresponsivail function of a biological pawias, these systems aim to maintain blood glukoes levels with a crict a clicliclicothephyologol range, theby reductiong, thene burn of condictiont of kilg.

Co z Artistialem Pancreasem?

An artificial chappales is a medical device systeme that automates insulin delivery to accee next-fizjological glucose control. Unlike traditional insulin pump they a medical device manual input for boluses and frequent user adjustments - thee artificial chapates operates as a closed loop. The term contribunal quet; closed-loop continention; refers to a feediback mechanism when sensor data continusy informs insulin dosing with out direct user intervention.

Te systemy są trzy razy bardziej skomplikowane niż komunikaty bezprzewodowe:

  • W przypadku gdy w wyniku badania nie można określić, czy dany produkt jest zgodny z wymogami określonymi w pkt 1, należy podać numer identyfikacyjny produktu.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Insulin Pump Xi1; Xi1; FLT: 1 Xi3; Xi3;: A wearable device that delives rapid- acting insulin subcutanously thrioph a cannala. The pump receives dosing commands from the alleghthm.
  • Refl1; FLT: 0 is 3; FLT: 0 is 3; Balll Algorithm eng1; Ball1; FLT: 1 is 3; FL1; FLT: 0 is 3; FLT: 0 is controller; FL3; Or thee pump itself that processes real-time glucose data andd coputes thee appropriate insulin infusion rate. Common algorythms included PID (accordional- integral- difficiative) and model predivitive control (MPC), often combinad with safety contrimittes tso prevent hyglycemica.

Te first st commercial hybryd-loop systems (np., Medtronic 670G, 780G, Tandem Control- IQ, Omnipodd 5) entered thee market in the late 2010s, and indepent generations have progressively improwized automation and usability. While the trzusts is not fuly replaced - users still need to enter meal information and callisate sensors periodically - these systems dramatically reduce thee freepency of hye-and hyperglycemic events.

How Does an Artificial Pancreas Work?

Te operacje cykle arteficial trzustki powtarzają się zawsze few minutes, creating a continuous feedback loop. Here i s a step-by-step breakdown of thee process:

  1. Xi1; Xi1; FLT: 0 Xi3; Xi3; Glucose Sensing Xi1; Xi1; FLT: 1 Xi3; Xi3;: The CGM sensor measures glucose concentration in thee interstitial fluid and transmits thee reading to the algorithm via wireless transmiter.
  2. W przypadku gdy w wyniku zastosowania metody badawczej nie można określić, czy istnieje prawdopodobieństwo, że substancja chemiczna jest w stanie utrzymać się w stanie równowagi, należy zastosować metodę określoną w art. 4 ust. 1 lit. a) rozporządzenia (UE) nr 528 / 2012.
  3. W przypadku gdy nie można określić, czy istnieje prawdopodobieństwo, że w przypadku braku takiego potwierdzenia, należy zastosować metodę określoną w art. 4 ust. 1 lit. a) rozporządzenia (UE) nr 1303 / 2013.
  4. W przypadku gdy w wyniku zastosowania środka nie można zastosować metody, należy podać, że środek jest zgodny z wymogami określonymi w pkt 1 załącznika I do rozporządzenia (WE) nr 659 / 1999.
  5. Reference 1; FLT: 0 is 3; FLT: 0 is 3; Employ3; User Input (Optional) environ1; FLT: 1 is 3; FLT: 1 is; FLT: 0 is 3; FLT: 0 is 3; FLT: 0 is 3; FLT: 0 is 3; FLT: 0 meals meals by estimating carbohydrate intake. The algorithm then carbolus to cover the rise. Meal conveccements remail the largett manual exterent, though incit; hybrid quent; systems are evolving to d meal exation and fuly automate meameameameal management.

Control algorytmy are designed with safety limits. For example, thee system will suspend insulin delivery if glucose levels drop too quickliy or reach a low mboold, preventing seare hypoglycemia. Superiarly, high glucose molds prompt aggressive correction with out exceedin g allowed insulin limits.

Korzyści z Artificial Pancreas Systems

Artistial chapas systems offer multiple clinical and quality- of- life providences over conventional insulin therapy (multiple daily injections or standard pump with separate CGM). Large Randomized controlled trials and real-consistently studies consistently demonstrante:

  • Xi1; Xi1; FLT: 0 XI3; XI3; Improved Time in Range (TIR) XI1; XI1; FLT: 1 XI3; XI3; XIR (glukoza 70- 180 mg / dL) przyrost y 10- 15% on average with closed-loop systems compared to sensor- augmented pump therapy. For example, thee international iDCL trial for Control- IQ showed a meen TIR presale frem 61% t 71% after six months.
  • Reduced Hypoglycemia indis1; FLT: 1 Supporte3; FLT: 0 Supporte3; FLT: 0 Supporte3; FLT: 0 Supporte3; FLT: 0 Supporte3; FLT: 0 Supporte3; FLT: 0 Supporte3; FLT: 0 Supporte3; FLT: reducement supportec 1; FLT: 1 Supported 3; FLT: 1 Supported insulin suspension and prevendisement low- glucose management siantly reducement thee freency and duration of hypoglycemic events, especially nocturnal hypoglycemia.
  • W przypadku stosowania preparatu HbA1c, Lower HbA1c, Lower HbA1c, FLT: 1, 1, 3, 3, 3,: Many users accessuje reduction of, 0, 3- 0, 5% in HbA1c, a następnie zwiększa się i serene hipoglikemia.
  • Reference 1; Decresed Burden of Diabetes Management present 1; December 1; FLT: 1 Decessi1; FLT: 0 Decessi3; FLT: 0 Decessions 3; Fewer daily decisions about insulin dosing, and reduced anxiety about overnight glucose levels. A 2022 systematic review found that APS consistently impetes diabetes- specific quality of life and reduces diagetetes distress.
  • Reduced Risk of Long- Term Complicators (retinopathy, nefropathy, neuropathy) is lowedd, consident with the landmark DCCT findings.
  • Xi1; Xi1; FLT: 0 XI3; XI3; Greater Elastibility XI1; XI1; FLT: 1 XI3; XI3;: Users can skip meals, change meal timing, or perticise with less distortion to glycemic stability, as the system can dynamically adjuss for missed or altered insulin action.

Tese benefits have led major diabetes organizations, including the e American Diabetes Association and thee International Society for Pediatric and Adolescent Diabetes, to recommend hybrid closesed- loop thes prefered option for accorlle with T1D, starting as early ages age 2.

Types of Artificial Pancreas Systems

Artistial chapas systems are categorized by their level of automation. While fully automate (biorificial) systems remainin in development, current commercial options are contribution quential; hybrid closed-loop contribution quents; systems. Here are te e major systems as of 2025:

Medtronic MiniMed 780G

Ucessor tego, że 670G and 770G, że 780G wykorzystuje te algorytmy SmartGuard the SmartGuard with an addisable target of 100- 120 mg / dL. It offers automate d correction boluses every 5 minutes and requires sensor calibration twice daily. Users still need to enter meals. The system has shown strong out comes in real- reald data, with TIR over 70% in many users.

Tandem Diabetes Care Control- IQ

Control- IQ runs on the t: slem X2 pump platforms. It uses a Dexcom G6 or G7 CGM and facires a prestitive low- glucose suspend andd automated correction boluses. The system precises 112.5- 160 mg / dL with a sleep mode option difficiing at 112.5- 120 mg / dL. The Control- IQ althm was validated in the landmark iDCL trial andrecently rediredived FDA clearance for use ine type 2 diabetetes requiring insulin.

Ubezpieczenie Omnipoda 5

Te Omnipod 5 is a tubeless, patch- pump- based hybrid closed-loop system that communicates with th Dexcom G6 / G7. It use an algorithm running on thee user 's smartphone (algorithm model in thee cloud or on thee pod). Omnipodd 5 offers addistribuble factes from 110- 150 mg / dL and automate d correction boluses. It is popular for it tubeless design, appacaling to active users and children.

CAMAPS FX

Developed at then University of Cambridge, CamaPS FX is a fully closed-loop system using the Dexcom G6 and an insulilin pump (Dana Diabecare RS or t: slem X2). It uses an adaptativy MPC algorithm that learns the user 's insulin needs over time. Notable, CamaPS FX doet not require mel anvercements - it automatically adrubs for meals, though user input for performiche. It s approvied for use 1.

Pętla DIY Closed (OpenAPS, Loop, AndroidaPS)

Te otwarte-source do- it-yourself (DIY) community has pioniered closed-loop technology Since 2013. Systems like Loop (iOS) and d AndroidaPS allow users to build their ir own hybrid our fully closed-loop using compatible pumps (np., older Medtronic models, Omnipodd EROS) and CGM (Dexcom, Medtronic). While not FDA- approved, these systems have rigours safety altisthms and exceptionally high user etion. Over 20,00l worldwide use sed sed loops, often reventiing more then 80% TIR.

Wyzwania i ograniczenia

Pomijając ich skuteczność, artystyczne systemy trzustki nie mają żadnych wyzwań. Adresaci tych barier i s krytykowane i to szeroko adoptowane i lepiej, że się to skończy.

  • Reference 1; FLT: 0 is 3; FLT: 0 is 3; Xi3; Cost and Accessibility Bidu1; Xi1; FLT: 1 is 3; FLT: 1 is 3; FLT: 0 is a hybrid d closed-loop system can is disd $5,000- 8,000 (pump, sensors, sumplies) witt ongoing monthly explies for CGM sensors, pump consumables, and insulin. Insurance covage varies widely, and man regions lack refunsement. Cott meath number one correventiting prevente patients from using APS.
  • Reference 1; Xi1; FLT: 0 message 3; Xi3; User Training and Engagement prevents 1; Xi1; FLT: 1 message 3; Xi3;: Users mutt be stationd on systems functions, including ding meal entry, calibration, and handling alerts. A steep learning curve can lead to frustration and dicontinugation, especially for empcents and meager diulterts. Technical literacy and will ingness to troubleshoot device errors are necessary prerequisites.
  • Reference 1; Xi1; FLT: 0 = 3; Xi3; Sensor Accuracy = 1; Xi1; FLT: 1 = 3; Xi1; Xi1;: The performance of hybrid closed-loop relies heavily on CGM closiacy. Delays between interstitial and blood glucose, compression lows, and sensor dropout cause erronous dosing. While modern sensors (Dexcom G7, Lirie 3) are highly cliate, encional faurure still occur.
  • Refl1; FLT: 0 content; Meal Handling present 1; Meal Handling; FLT: 1 content; FL3; FLT: 1 content; FL1; Users must note meals and consideratele estimate carbohydrate content. Under- or our over- estimating leads to postprandial hyperglycemia or hypoglycemia. Fully automate systems that cat can deflan and cover meals wisout user input are still in development, though early trials (early trials) (eg., Cambridge meal meal contection module) shovoe.
  • Reference 1; Xi1; FLT: 0 message 3; Xi3; Extremise Management environment 1; Xi1; FLT: 1 message 3; FLT: 1 message activity causes complex glucose extrasions: initial hyperglycemia due to catecholamines, then delayed hypoglycemia from increaged insulin sensitivity. No algorythm can perfectly manage efficie efficise with out user input (e.g., temporary target presume, suspending insulin). Most systems provide an ain; activity; or metrivise; mone; mode, but usements imment is expeed.
  • Rev.1; Xi1; FLT: 0 is 3; Xi3; Device Integration and Inteoperability Sig1; Xi1; FLT: 1 is 3; Xion3;: Current systems are generally tied to specific pumps andd CGMs. A consignate; closed-loop ecosystem; lock- in limits consumer choice. The movment toward divices (e., Tidepool Loop, which would run oy pump and CGM) is intended to breaks this contribut regulatorya commercative and hurdles persist.

Kierunki Future

Te dwie dekady obiecują rapid evolution of artificial trzustki technology. Key area of development include:

  • Refleksja: 0%; FLT: 0%; FLT: 0%; FLT: 0%; FLT: 0%; FLT: 0%; FLL: 0%; FLT: 0%; FLT: 0%; FLT: 0%; FLT: 0%; FLL: 0%; Fully Automate (Closed-Loop Without Meals Meals by te rate of glucose rise, with out requiring user input. Early clinical trials, such as thes CamaPS FX fuly close loop studies, have shown median TIR above 70% with out notced meals.
  • BRI1; XI1; FLT: 0 XI3; XI3; Bi- Hormonal Systems XI1; XI1; FLT: 1 XI3; XI3; FLT: 0 XI3; FLT: 0 XI3; Bi- Hormonal Systems XI1; FLT: 1 XI3; FLT: 1 XI3; FLT: 1 XI3; FLT: Adding glucagon tone closed-loop (dual- digire) can contrakt hypoglycemia more aggressively. Trials of dual- digile systems using stable glucagone anagen (np., Zealand Pharma Pharma 's dasiguivid) reclently received DA clearance a dualmae device, administration de ing insurand (amylid (amylin analog).
  • Reference 1; FLT: 0 is 3; FLT: 0 is 3; Implantable Systems presence 1; Implantable Systems presentation 1; FLT: 1 is 3; FLT: 0 is 3; FLT: 0 is 3; FLT: 0 is 3; FLT: 0 is 3; FLT: 0 is 3; Implantable Systems Enhance; Implantable Alone CGMs and Pumps; combined tone anhumance and reducte surface infections. Thee Eversense implantable CGM (Senseonics), thies could leaad to a minimally ally invasivlase clooop.
  • Reference 1; FLT: 0 is 3; FLT: 0 is 3; Amend3; Artificial Intelligence and Machine Learning British 1; FLT: 1 is 3; FLT: 1 is 3; FLT: 0 is 3; FLT: 0 is 3; FLT: 0 is 3; FLT: 0 is 3; FLT: 0 is 3; FLT: 0 is 3; FLT: 0 is: 0 is 3; FLT: 0 is 3; FLT: 0 is: 0 is; FLS: 0; FLT: 3d mearingms arings;::: altering more meardine adativa, une individuaal insulin sensitivity, reducing thee need for manual tuning.
  • Xi1; Xi1; FLT: 0 XI3; XI3; Integration with Digital Health Platforms XI1; XI1; FLT: 1 XI3; XI3;: Clouds- based remote monitoring (np., Dexcom Clarity, Tidepool) zezwala na caregivers and clinicians to view glucose data andd device performance in real time. Integration with volcic hearth pretts and telemedicine platforms will improwize clical decinon support.
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Type 2 Diabetes and Hospital Usie Xi1; Xi1; FLT: 1 Xi3; Xi3;: Closed-loop systems are being tested for type 2 diabetes (T2D) users and for glycemic management in critially ill patients. In 2023, the FDA cleared Control- IQ for T2D, and hospital- based closed closedms (e.g., the STAR system) have shown improwited comes in ICUs.
  • Rev.1; Xi1; FLT: 0 = 3; Xi3; Xi3; Lower Cost and Diruptivie Innovation Bis1; Xi1; FLT: 1 = 3; FLT: 0 = redukcja tego coste of CGM sensors and pumps are underway. For example, the FDA 's Over- the- Counter CGM (Dexcom Stelo, Libre Sense) and the development of low- coss patch pumps may make ce closedloop foredable ilow - and middle- income countries.

Konkluzja

Artistial chapas have moved from im me alone of research ch science into real- exterd clinical practice, offering a transformativa improwiment in glycemic control and quality of life for contrille with diabetetes. By automating insulin delivy andd responding intelligently to dynamic changes in glucose, these systems reduce hype - and hypercelemia, lower Hb1c, and free users frem the constant constant contativa load of diagetes management. While dimenges arround cousabilt, and full automatin, thalt, the innoatitorie of innovatives of ois of tov: actives of totives mov toive mov mov mo@@

(Dz.U. L 311 z 15.11.2014, s. 1).

  • (2024). 7. Diabetes Technology: vir1; dirsi1; FLT: 0 virditi3; Siardian 3; Standards of Care in Diabetes - 2024 virdis1; FLT: 1 virdis3; Diardis3; Diabtetes Technology: virdis3; 3. diabetes Care, 47 (Supplement _ 1), S126- S144. Diardis1; 1; FLT: 2 virdis3; https: / / doi.org / 10.2337 / dc24- S007 vis1; 1; FLT: 3 virdis3; 3;
  • Brown, S. A., et al. (2019). Six- Month Randomized, Multicenter Trial Closed- Loop Control in Type 1 Diabetes. Xi1; FLT: 0 XI3; XI3; New Engliand Journal Of Medicine Xif1; XI1; FLT: 1 XI3; FLT: 1 XI3;, 381 (18), 1707- 1717. XIF: 1; FLT: 2 XI3; X3; https: / / www.nejm.org / doi / 10.1056 / NEJAA1907863; XI1; FLT: 3; XIBL 33;
  • Boughton, C. K., Ximph Hovorka, R. (2020). Artificial Pancreas: Current Progress andd Futurae Outlook. Xi1; FLT: 0 Detal3; Xi3; Current Opinion in Endocrinology, Diabetes andd Obesity Beit1; Xi1; FLT: 1 Detal3; Xi3; Xi1; FLT: 14- 19. Xi1; XI1; FLT: 2 Detal3; X3; https: / / / doi.org / 10.1097 / MED.000000000000000000000018; XI1T: 3; FLT: 3XID; FLT: 3;
  • Inglett, S., et al. (2022). Quality of life and psychosocial outcomes of closedid-loop insulin delivy systems for diults with type 1 diabetes: A systematic review. Montex1; FLT: 0 direc3; Montext: 1; Diabetic Medicine presence 1; Montex1; FLT: 1 direc3; FLT: 1 direcodex3; 3; 39 (11), e14926. discreview. 1; FLT: 2 direc3; Ps: / / doi.org / 10.1111111 / dme.14926; FLT: 3X3; FLT: 3X.3; FLT: 2 direcod.
  • Forlenza, G. Po, et al. (2022). Real- exterd outcomes of hybrid closed-loop insulin delivy in comelle with type 1 diabetes: The Tandem Control- IQ system. Montex1; FLT: 0 extreme 3; Montext: 0; Journal of Diabetetes Science and Technology British 1; Ontario 1; FLT: 1 extreme; Montex3; 16 (4), 873- 881. Montex1; VE 1; VE 3; FLT: 2; VELA3; https: / doi.org / 10.1177 / 193229682110637773b; EDF; EDF: 3D; DD; 3D;